Cargando…

Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer

BACKGROUND: Tamoxifen (TAM) and Toremifene (TOR), two kinds of selective estrogen receptor modulators (SERMs), have equal efficacy in breast cancer patients. However, TAM has been proved to affect serum lipid profiles and cause fatty liver disease. The study aimed to compare the effects of TAM and T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Dandan, Hu, Yingying, Diao, Biyu, Miao, Rongrong, Zhang, Baodan, Cai, Yangjun, Zeng, Hanqian, Zhang, Yuru, Hu, Xiaoqu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272257/ https://www.ncbi.nlm.nih.gov/pubmed/34246237 http://dx.doi.org/10.1186/s12885-021-08538-5

Ejemplares similares

Long Non-Coding RNA NLIPMT as a Tumor Suppressor and Inhibitor of Cell Proliferation and Metastasis in Papillary Thyroid Carcinoma
por: Zhang, Fen, et al.
Publicado: (2020)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Circumvention of Daunorubicin Resistance by a New Tamoxifen Derivative, Toremifene, in Multidrug‐resistant Cell Line
por: Urasaki, Yoshimasa, et al.
Publicado: (1994)

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
por: Wang, Hongyue, et al.
Publicado: (2021)

Toremifene interacts with and destabilizes the Ebola virus glycoprotein
por: Zhao, Yuguang, et al.
Publicado: (2016)

A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study
por: Gu, Ran, et al.
Publicado: (2012)

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
por: PyrhÃ¶nen, S., et al.
Publicado: (1997)

Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene
por: Balducci, Chiara, et al.
Publicado: (2005)

Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
por: Shien, Tadahiko, et al.
Publicado: (2017)

High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
por: Mori, Ryutaro, et al.
Publicado: (2014)

Inhibitory Effects of Toremifene on N‐Methyl‐N‐nitrosourea and Estradiol‐17β‐induced Endometrial Carcinogenesis in Mice
por: Niwa, Kenji, et al.
Publicado: (2002)

Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007)

High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors
por: Fushimi, Atsushi, et al.
Publicado: (2020)

Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocyte) and tamoxifen
Publicado: (2000)

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
por: Henriksson, R., et al.
Publicado: (1998)

Association of tamoxifen resistance and lipid reprogramming in breast cancer
por: Hultsch, Susanne, et al.
Publicado: (2018)

Effects of Toremifene, a Selective Estrogen Receptor Modulator, on Spontaneous and Stimulated GH Secretion, IGF-I, and IGF-Binding Proteins in Healthy Elderly Subjects
por: Roelfsema, Ferdinand, et al.
Publicado: (2017)

Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply
Publicado: (2000)

Therapeutic Effects of a Traditional Chinese Medicine Formula Plus Tamoxifen vs. Tamoxifen for the Treatment of Mammary Gland Hyperplasia: A Meta-Analysis of Randomized Trials
por: Li, Hao-Tian, et al.
Publicado: (2018)

Uridine prevents tamoxifen-induced liver lipid droplet accumulation
por: Le, Thuc T, et al.
Publicado: (2014)

MGDB: a comprehensive database of genes involved in melanoma
por: Zhang, Di, et al.
Publicado: (2015)

Effect of different lipids and surfactants on formulation of solid lipid nanoparticles incorporating tamoxifen citrate
por: Upadhyay, S. U., et al.
Publicado: (2012)

Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
por: Fujimura, Tetsuya, et al.
Publicado: (2015)

Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism
por: Diot, Cédric, et al.
Publicado: (2022)

Tamoxifen retinopathy: a case report
por: Wang, Lingling, et al.
Publicado: (2015)

Contrast-Enhanced Ultrasound: An Effective Method for Noninvasive Diagnosis of Mummified Thyroid Nodules
por: Zhang, Hong, et al.
Publicado: (2022)

Tamoxifen induces fatty liver disease in breast cancer through the MAPK8/FoxO pathway
por: Gong, Liuyun, et al.
Publicado: (2020)

New Dibenzo-α-pyrone Derivatives with α-Glucosidase Inhibitory Activities from the Marine-Derived Fungus Alternaria alternata
por: Zhang, Jinxin, et al.
Publicado: (2022)

Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen
por: Cheng, Yung-Yi, et al.
Publicado: (2022)

IARC on tamoxifen.
Publicado: (1996)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer
por: Yoo, Jeong-Ju, et al.
Publicado: (2020)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)
por: HU, RONG, et al.
Publicado: (2015)

Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids
por: Vehmanen, L, et al.
Publicado: (2004)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ojcgaskkd4gcqhb2bkbcf6ivmv